Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy

Published:2021-06 Issue:6 Volume:16 Page:1030-1041
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Aredo Jacqueline V.,Mambetsariev Isa,Hellyer Jessica A.,Amini Arya,Neal Joel W.,Padda Sukhmani K.,McCoach Caroline E.,Riess Jonathan W.,Cabebe Elwyn C.,Naidoo Jarushka,Abuali Tariq,Salgia Ravi,Loo Billy W.,Diehn Maximilian,Han Summer S.,Wakelee Heather A.

Funder

Merck

Roche

AstraZeneca

National Cancer Institute

National Institutes of Health

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference37 articles.

1. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer;Antonia;N Engl J Med,2017

2. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer;Senan;J Clin Oncol,2016

3. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: cancer and leukemia group B trial 30407;Govindan;J Clin Oncol,2011

4. Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer;Bradley;J Clin Oncol,2020

5. EGFR mutation impact on definitive concurrent chemoradiation therapy for inoperable stage III adenocarcinoma;Tanaka;J Thorac Oncol,2015

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reduced frequency and severity of radiation esophagitis without marginal failure risk by contralateral esophagus sparing IMRT in stage III non-small cell lung cancer patients undergoing definitive concurrent chemoradiotherapy;Radiotherapy and Oncology;2024-10

2. Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario;Current Oncology;2024-08-30

3. Advances and future directions in ROS1 fusion-positive lung cancer;The Oncologist;2024-08-23

4. Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC;New England Journal of Medicine;2024-08-15

5. Treatment Response Biomarkers: Working Toward Personalized Radiotherapy for Lung Cancer;Journal of Thoracic Oncology;2024-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3